For this design, we utilized the atezolizumab scaffold, an antibody targeting the tumor-associated programmed death-ligand 1 (PD-L1) approved for immune checkpoint blockade, to potentially enhance the PFP’s anti-tumor activity. This evidence concerns the gene PRF1 and neoplasm.